Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command (USAMRDC) to support a U.S. Army Military Performance Advancement Initiative (MPAI) project to develop new treatments for COVID-19 and other SARS infections.